{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maxidex&page=2", "query": { "intervention": "Maxidex", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maxidex&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-09T22:55:51.645Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02219581", "title": "Steroids in Total Knee Arthroplasty", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postoperative Pain", "Inflammation", "Osteoarthritis" ], "interventions": [ { "name": "Dexamethasone 10 mg", "type": "DRUG" }, { "name": "Dexamethasone 20 mg", "type": "DRUG" }, { "name": "Standard multimodal pain management regimen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas L Bradbury", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1, "start_date": "2014-10-16", "completion_date": "2015-12-01", "has_results": true, "last_update_posted_date": "2022-10-04", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 1, "location_summary": "Tucker, Georgia", "locations": [ { "city": "Tucker", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219581" }, { "nct_id": "NCT02343042", "title": "Selinexor and Backbone Treatments of Multiple Myeloma Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Belantamab Mafodotin", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2015-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343042" }, { "nct_id": "NCT02419469", "title": "Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Precursor-B Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma", "Lymphoma" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "PEG asparaginase", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexamethasone acetate", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Years to 30 Years" }, "enrollment_count": 1, "start_date": "2015-11-13", "completion_date": "2017-06-22", "has_results": true, "last_update_posted_date": "2018-06-11", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419469" }, { "nct_id": "NCT02135874", "title": "Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Leukemia of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Mixed Phenotype Acute Leukemia", "Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified", "Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified", "Recurrent Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-10-27", "completion_date": "2023-02-21", "has_results": true, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02135874" }, { "nct_id": "NCT00574080", "title": "UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Interim/Maintenance Dexamethasone", "type": "DRUG" }, { "name": "Induction/Consolidation Dexamethasone", "type": "DRUG" }, { "name": "Induction/Consolidation Cisplatin", "type": "DRUG" }, { "name": "Induction/Consolidation Adriamycin", "type": "DRUG" }, { "name": "InductionConsolidation Cyclophosphamide", "type": "DRUG" }, { "name": "Induction/Consolidation Etoposide", "type": "DRUG" }, { "name": "Induction Pegfilgrastim", "type": "DRUG" }, { "name": "Transplant 1 Dexamethasone", "type": "DRUG" }, { "name": "Transplant 1 Cisplatin", "type": "DRUG" }, { "name": "Transplant 1 Adriamycin", "type": "DRUG" }, { "name": "Transplant 1 Cyclophosphamide", "type": "DRUG" }, { "name": "Transplant 1 Etoposide", "type": "DRUG" }, { "name": "Transplant 1 Melphalan", "type": "DRUG" }, { "name": "Transplant 1 and 2 Pegfilgrastim", "type": "DRUG" }, { "name": "Autologous Peripheral Blood Stem Cell Transplant (ASCT)", "type": "PROCEDURE" }, { "name": "Transplant 2 Carmustine", "type": "DRUG" }, { "name": "Transplant 2 Etoposide", "type": "DRUG" }, { "name": "Transplant 2 Cytarabine", "type": "DRUG" }, { "name": "Transplant 2 Melphalan", "type": "DRUG" }, { "name": "Transplant 2 Dexamethasone", "type": "DRUG" }, { "name": "Transplant 1 and 2 Bortezomib", "type": "DRUG" }, { "name": "Transplant 1 and 2 Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2006-07", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574080" }, { "nct_id": "NCT03367988", "title": "Opioid Free Anesthesia vs. Opioid Anesthesia Techniques.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Analgesic Drug Dependence", "Colectomy" ], "interventions": [ { "name": "Opioid Anesthesia", "type": "DRUG" }, { "name": "Opioid-free Anesthesia", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 100, "start_date": "2018-12-01", "completion_date": "2023-08", "has_results": false, "last_update_posted_date": "2022-05-25", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03367988" }, { "nct_id": "NCT01470131", "title": "A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Masitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AB Science", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2011-05", "completion_date": "2017-02-01", "has_results": false, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 5, "location_summary": "Galesburg, Illinois • Bethesda, Maryland • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Galesburg", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Goldsboro", "state": "North Carolina" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01470131" }, { "nct_id": "NCT04123561", "title": "Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis of the Knee" ], "interventions": [ { "name": "TLC599", "type": "DRUG" }, { "name": "DSP", "type": "DRUG" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Taiwan Liposome Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 504, "start_date": "2019-11-26", "completion_date": "2022-02-03", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04123561" }, { "nct_id": "NCT01531998", "title": "Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Siltuximab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2012-05", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-06-19", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01531998" }, { "nct_id": "NCT05626478", "title": "Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Corneal Edema", "Corneal Defect", "Anterior Chamber Inflammation", "Ocular Pain", "Corneal Staining", "Visual Outcome", "CME - Cystoid Macular Edema" ], "interventions": [ { "name": "Dextenza 0.4Mg Ophthalmic Insert", "type": "DRUG" }, { "name": "Prednisolone Acetate 1% Oph Susp", "type": "DRUG" }, { "name": "Prolensa 0.07% Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicole Fram M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-06-01", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-09-09T22:55:51.645Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05626478" } ] }